Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir

Conflicting drug-drug interaction (DDI) studies with the HIV protease inhibitors (PIs) suggest net induction or inhibition of intestinal or hepatic CYP3A. As part of a larger DDI study in healthy volunteers, we determined the effect of extended administration of two PIs, ritonavir (RTV) or nelfinavir (NFV), or the induction-positive control rifampin on intestinal and hepatic CYP3A activity as measured by midazolam (MDZ) disposition after a 14-day treatment with the PI in either staggered (MDZ ∼12 h after PI) or simultaneous (MDZ and PI coadministered) manner. Oral and intravenous MDZ areas under the plasma concentration-time curves were significantly increased by RTV or NFV and were decreased by rifampin. Irrespective of method of administration, RTV decreased net intestinal and hepatic CYP3A activity, whereas NFV decreased hepatic but not intestinal CYP3A activity. The magnitude of these DDIs was more accurately predicted using PI CYP3A inactivation parameters generated in sandwich-cultured human hepatocytes rather than human liver microsomes.

[1]  J. Unadkat,et al.  Impact of Ignoring Extraction Ratio When Predicting Drug-Drug Interactions, Fraction Metabolized, and Intestinal First-Pass Contribution , 2010, Drug Metabolism and Disposition.

[2]  D. Greenblatt,et al.  Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. , 2009, British journal of clinical pharmacology.

[3]  Alex Phipps,et al.  Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.

[4]  M Jamei,et al.  Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.

[5]  Tristan S. Maurer,et al.  A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.

[6]  J. Unadkat,et al.  Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors , 2008, Drug Metabolism and Disposition.

[7]  P. Zhao.  The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo , 2008, Expert opinion on drug metabolism & toxicology.

[8]  C. Hughes,et al.  Interaction between lopinavir/ritonavir and warfarin , 2007, Canadian Medical Association Journal.

[9]  N. Hariparsad,et al.  Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions , 2007, Drug Metabolism and Disposition.

[10]  Karthik Venkatakrishnan,et al.  Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.

[11]  E. Kharasch,et al.  Simultaneous Measurement of In Vivo P‐glycoprotein and Cytochrome P450 3A Activities , 2006, Journal of clinical pharmacology.

[12]  T. Maurer,et al.  Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction , 2006, Drug Metabolism and Disposition.

[13]  D. Greenblatt,et al.  Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir , 2006, Clinical pharmacology and therapeutics.

[14]  C. Ernest,et al.  Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[15]  E. Kharasch,et al.  Intravenous and oral alfentanil as in vivo probes for hepatic and first‐pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis , 2004, Clinical pharmacology and therapeutics.

[16]  R. Zeldin,et al.  Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.

[17]  D. Greenblatt,et al.  Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice , 2003, Clinical pharmacology and therapeutics.

[18]  D. Greenblatt,et al.  Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[19]  Shiew-Mei Huang,et al.  The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity , 2001, Clinical pharmacology and therapeutics.

[20]  D. Greenblatt,et al.  Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir , 2000, Journal of acquired immune deficiency syndromes.

[21]  D. Greenblatt,et al.  Alprazolam‐ritonavir interaction: Implications for product labeling , 2000, Clinical pharmacology and therapeutics.

[22]  G. Plosker,et al.  Nelfinavir , 2000, Drugs.

[23]  S. Webber,et al.  Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[24]  P. Vouros,et al.  Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[25]  J. Leonard,et al.  Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects , 1997, Antimicrobial agents and chemotherapy.

[26]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[27]  A. D. Rodrigues,et al.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.